open access
Correlation between glycaemic variability and prognosis in diabetic patients with CKD
Affiliations- Nephrology Department, Jinan University First Affiliated Hospital, Guangzhou, China
- Health Management Center Physical Examination Department, Longgang District People’s Hospital of Shenzhen, Shenzhen, China
- Jinan University College of Information Science and Technology, Guangzhou, China
open access
Abstract
Introduction: Glycaemic variability (GV), rather than glucose level, has been shown to be an important factor associated with in-hospital mortality. The coefficient of variation of glucose (GLUCV) is one of the methods used to evaluate GV. However, the clinical significance of GLUCV in diabetes mellitus (DM) patients diagnosed with chronic kidney disease (CKD) as a risk factor for long-term adverse changes is unknown.
Material and methods: In this retrospective study, we extracted data of adult DM patients diagnosed with CKD from the Medical Information Mart for Intensive Care (MIMIC-IV). We sought to investigate the relationship between GV and in-hospital mortality as well as 30-day mortality. A non-parametric test was used to compare baseline characteristics between groups. Kaplan-Meier analysis and Cox regression model were used to analyse the risk factors associated with in-hospital and 30-day mortality.
Results: A total of 1572 DM patients with CKD were included in our data analysis. The quartile of the GLUCV values was used to assign subjects to 4 groups: GLUCV1 (GLUCV < 24), GLUCV2 (24 ≤ GLUCV < 31), GLUCV3 (31 ≤ GLUCV < 39) and GLUCV 4 (GLUCV ≥ 39). COX regression analysis revealed that the GLUCV was an independent risk factor for in-hospital and 30-day mortality [GLUCV2 group (HR = 0.639, 95% CI: 0.454–0.899, p = 0.010), GLUCV3 group (HR = 0.668, 95% CI: 0.476–0.936, p = 0.019), and GLUCV3 group (HR = 0.726, 95% CI: 0.528–0.999, p = 0.049)]. The Kaplan-Meier survival curve was steeper in the GLUCV1 and GLUCV4 groups, and the survival rate decreased in a time-dependent manner.
Conclusions: Herein, we validated GV as a mortality risk factor for DM patients with CKD. Therefore, monitoring and adjusting GV in hospitalized patients might have a significant treatment benefit.
Abstract
Introduction: Glycaemic variability (GV), rather than glucose level, has been shown to be an important factor associated with in-hospital mortality. The coefficient of variation of glucose (GLUCV) is one of the methods used to evaluate GV. However, the clinical significance of GLUCV in diabetes mellitus (DM) patients diagnosed with chronic kidney disease (CKD) as a risk factor for long-term adverse changes is unknown.
Material and methods: In this retrospective study, we extracted data of adult DM patients diagnosed with CKD from the Medical Information Mart for Intensive Care (MIMIC-IV). We sought to investigate the relationship between GV and in-hospital mortality as well as 30-day mortality. A non-parametric test was used to compare baseline characteristics between groups. Kaplan-Meier analysis and Cox regression model were used to analyse the risk factors associated with in-hospital and 30-day mortality.
Results: A total of 1572 DM patients with CKD were included in our data analysis. The quartile of the GLUCV values was used to assign subjects to 4 groups: GLUCV1 (GLUCV < 24), GLUCV2 (24 ≤ GLUCV < 31), GLUCV3 (31 ≤ GLUCV < 39) and GLUCV 4 (GLUCV ≥ 39). COX regression analysis revealed that the GLUCV was an independent risk factor for in-hospital and 30-day mortality [GLUCV2 group (HR = 0.639, 95% CI: 0.454–0.899, p = 0.010), GLUCV3 group (HR = 0.668, 95% CI: 0.476–0.936, p = 0.019), and GLUCV3 group (HR = 0.726, 95% CI: 0.528–0.999, p = 0.049)]. The Kaplan-Meier survival curve was steeper in the GLUCV1 and GLUCV4 groups, and the survival rate decreased in a time-dependent manner.
Conclusions: Herein, we validated GV as a mortality risk factor for DM patients with CKD. Therefore, monitoring and adjusting GV in hospitalized patients might have a significant treatment benefit.
Keywords
diabetes; chronic kidney disease; coefficient of variation of glucose; prognosis
About this articleTitle
Correlation between glycaemic variability and prognosis in diabetic patients with CKD
Journal
Issue
Article type
Original paper
Pages
947-953
Published online
2022-12-09
Page views
3626
Article views/downloads
505
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2022;73(6):947-953.
Keywords
diabetes
chronic kidney disease
coefficient of variation of glucose
prognosis
Authors
Mingshuang Gao
Zhihua Zhong
Ya Yue
Fanna Liu
References (28)- Anders HJ, Huber TB, Isermann B, et al. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018; 14(6): 361–377.
- Koro CE, Lee BoH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009; 31(11): 2608–2617.
- Garla V, Kanduri S, Yanes-Cardozo L, et al. Management of diabetes mellitus in chronic kidney disease. Minerva Endocrinol. 2019; 44(3): 273–287.
- Tong L, Chi C, Zhang Z. Association of various glycemic variability indices and vascular outcomes in type-2 diabetes patients: A retrospective study. Medicine (Baltimore). 2018; 97(21): e10860.
- De Cosmo S, Copetti M, Lamacchia O, et al. Development and validation of a predicting model of all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2013; 36(9): 2830–2835.
- McEwen LN, Karter AJ, Waitzfelder BE, et al. Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD). Diabetes Care. 2012; 35(6): 1301–1309.
- Hirsch IB. Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does! Diabetes Care. 2015; 38(8): 1610–1614.
- DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes. 2013; 62(5): 1405–1408.
- Rodbard D. Clinical interpretation of indices of quality of glycemic control and glycemic variability. Postgrad Med. 2011; 123(4): 107–118.
- Lin CC, Li CI, Liu CS, et al. Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med. 2012; 125(4): 416.e9–416.18.
- Lin CC, Li CI, Liu CS, et al. Annual fasting plasma glucose variation increases risk of cancer incidence and mortality in patients with type 2 diabetes: the Taichung Diabetes Study. Endocr Relat Cancer. 2012; 19(4): 473–483.
- Zoppini G, Verlato G, Targher G, et al. Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. Diabetes Metab Res Rev. 2008; 24(8): 624–628.
- Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007; 50(11): 2239–2244.
- DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes. 2013; 62(5): 1405–1408.
- Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014; 37(8): 2359–2365.
- Folli F, Corradi D, Fanti P, et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev. 2011; 7(5): 313–324.
- Bruginski D, Précoma DB, Sabbag A, et al. Impact of Glycemic Variability and Hypoglycemia on the Mortality and Length of Hospital Stay among Elderly Patients in Brazil. Curr Diabetes Rev. 2020; 16(2): 171–180.
- Johnson A, Bulgarelli L, Pollard T, et al. MIMIC-IV (version 0.4). PhysioNet 2020.
- Krinsley JS. Glycemic variability and mortality in critically ill patients: the impact of diabetes. J Diabetes Sci Technol. 2009; 3(6): 1292–1301.
- American Diabetes Association. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2020; 43(Suppl 1): S14–S31.
- Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020; 97(6): 1117–1129.
- Lee CL, Chen CH, Wu MJ, et al. The variability of glycated hemoglobin is associated with renal function decline in patients with type 2 diabetes. Ther Adv Chronic Dis. 2020; 11: 2040622319898370.
- Service FJ. Glucose variability. Diabetes. 2013; 62(5): 1398–1404.
- Ali NA, O'Brien JM, Dungan K, et al. Glucose variability and mortality in patients with sepsis. Crit Care Med. 2008; 36(8): 2316–2321.
- Dossett LA, Cao H, Mowery NT, et al. Blood glucose variability is associated with mortality in the surgical intensive care unit. Am Surg. 2008; 74(8): 679–85; discussion 685.
- Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med. 2008; 36(11): 3008–3013.
- Frontoni S, Di Bartolo P, Avogaro A, et al. Glucose variability: An emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract. 2013; 102(2): 86–95.
- Weber C, Schnell O. The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther. 2009; 11(10): 623–633.
